Following approval in the UK in 2017, Humedics has now also received Marketing Authorization for its diagnostic agent, LiMAxetin®, in Germany and Austria.
Humedics, Portfolio News
British NICE Institute: Positive assessment of the Humedics LiMAx® test
- Medtech Innovation Briefing (MIB) published by the National Institute for Health and Care Excellence
- Point-of-care measurement of the non-invasive breath test emphasised as especially innovative
- Possible cost savings to the UK National Health System are addressed
Independent trial shows accurate staging of liver fibrosis with the LiMAx® test
Clinical study from the University of Essen reveals superiority of the LiMAx® test for noninvasively detecting different stages of fibrosis and cirrhosis in patients with chronic liver disease
Safer liver resection: Perioperative assessment of liver function with the LiMAx® test shortens hospital stay and reduces complications after liver surgery
Clinical phase III trial at 6 specialized liver centers demonstrates impressive benefits of the LiMAx® test.
The LiMAx® test is now commercially available in the UK
Humedics receives UK Marketing Authorization for its diagnostic agent, LiMAxetin®, and thus achieves full market clearance for the LiMAx® maximum liver capacity test in the UK, – the company’s first in Europe!
Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO
Reinforcement of senior management team to leverage growth phase of Humedics
Berlin. The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de Buijzer will stay on as managing director (MD) with the title Chief Operations Officer (COO). Read more
LiMAx test enables better timing of liver surgery for colorectal liver metastatic patients after chemotherapy
Determination of liver function is crucial to assess patient’s eligibility for safe liver resection
Berlin. Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that two studies show the potential of the LiMAx test to better assess the eligibility of colorectal cancer patients for liver metastases resection after chemotherapy. The LiMAx test was used to explore the effects of oxaliplatin-based chemotherapy on liver function. Read more
Use of LiMAx test leads to reduction in post-hepatectomy liver failure and related mortality
Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced results of a retrospective study investigating the impact of the LiMAx test on clinical patient outcome after hepatectomy. Study results showed that the use of the LiMAx test led to reductions in post-operative liver failure and to a decrease of liver failure related mortality. Read more
